期刊
CLINICAL AND TRANSLATIONAL IMAGING
卷 2, 期 4, 页码 321-330出版社
SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s40336-014-0073-z
关键词
PET; Dementia; Alzheimer's disease; Atrophy; Cerebral glucose metabolism; Amyloid
资金
- AVID radiopharmaceuticals
Positron emission tomography (PET) with FDG or amyloid tracers is an important diagnostic tool, which also provides imaging biomarkers for patient selection in therapeutic trials in Alzheimer's disease. PET is also a quantitative technique with the potential to measure disease severity and progression. Limitations in spatial resolution result in partial volume effects that can be minimized by correction algorithms and image reconstruction with resolution recovery. Quantitative local rates of cerebral glucose metabolism can be calculated from FDG uptake. Reaching the highest degree of accuracy still requires blood sampling, while bloodless techniques have improved and can provide useful approximations. Advanced image processing techniques allow semiautomatic standardised assessment of diagnostic metabolic patterns and disease severity. Amyloid imaging provides excellent categorical classification of fibrillary amyloid deposition, but quantitative measures derived from amyloid tracer uptake are less well understood.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据